A groundbreaking drug, lorlatinib, has shown remarkable success in treating non-small cell lung cancer, or NSCLC, by significantly prolonging progression-free survival. In a phase three trial with 296 patients at Peter MacCallum Cancer Center, Melbourne, 60% of those given the drug were still alive without disease progression after five years, compared to only 8% in the control group. This third-generation ALK-inhibitor has shown unprecedented results, although it may lead to higher non-cancer adverse events, which can be managed by adjusting the dosage without compromising its efficacy against NSCLC.